Citation Formats
Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

N. Yilmaz Et Al. , "Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide," 11th International Congress on Systemic Lupus Erythematosus , vol.33, Vienna, Austria, 2015

Yilmaz, N. Et Al. 2015. Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide. 11th International Congress on Systemic Lupus Erythematosus , (Vienna, Austria).

Yilmaz, N., Emmungil, H., Gucenmez, S., Ozen, G., Yildiz, F., Balkarli, A., ... Kimyon, G.(2015). Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide . 11th International Congress on Systemic Lupus Erythematosus, Vienna, Austria

Yilmaz, N. Et Al. "Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide," 11th International Congress on Systemic Lupus Erythematosus, Vienna, Austria, 2015

Yilmaz, N. Et Al. "Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide." 11th International Congress on Systemic Lupus Erythematosus , Vienna, Austria, 2015

Yilmaz, N. Et Al. (2015) . "Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide." 11th International Congress on Systemic Lupus Erythematosus , Vienna, Austria.

@conferencepaper{conferencepaper, author={N. Yilmaz Et Al. }, title={Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide}, congress name={11th International Congress on Systemic Lupus Erythematosus}, city={Vienna}, country={Austria}, year={2015}}